FindTrial
Sign In

AN OPEN, MULTICENTRE, RANDOMISED, PARALLEL GROUP STUDY TO COMPARE IN MARGINAL OLD-FOR-OLD RENAL TRANSPLANT PATIENTS THE SAFETY AND EFFICACY OF TWO TREATMENTS: SEQUENTIAL MYCOPHENOLATE MOFETIL / DELAYED TACROLIMUS PLUS STEROIDS VS TACROLIMUS PLUS MYCOPHENOLATE MOFETIL IN PATIENTS REQUIRING INDUCTION WITH ANTI-IL2 MONOCLONAL ANTIBODY

AN OPEN, MULTICENTRE, RANDOMISED, PARALLEL GROUP STUDY TO COMPARE IN MARGINAL OLD-FOR-OLD RENAL TRANSPLANT PATIENTS THE SAFETY AND EFFICACY OF TWO TREATMENTS: SEQUENTIAL MYCOPHENOLATE MOFETIL / DELAYED TACROLIMUS PLUS STEROIDS VS TACROLIMUS PLUS MYCOPHENOLATE MOFETIL IN PATIENTS REQUIRING INDUCTION WITH ANTI-IL2 MONOCLONAL ANTIBODY

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-001205-99-IT
Enrollment
Unknown
Registered
2005-01-12
Start date
2004-07-19
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prevention of rejection of marginal old-for-old renal transplant

Interventions

Trade Name: PROGRAF*100CPS 0,5MG Product Name: Prograf Pharmaceutical Form: Capsule, hard INN or Proposed INN: Tacrolimus CAS Number: 104987-11-3 Concentration unit: mg milligram(s) Concentration ty

Sponsors

FUJISAWA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026